The information in news releases is current at the time of the release. Note that the information shown here may not be latest information (termination of production or sales, changes to specifications or pricing, organizational or contact address changes, etc.), and may be subject to change without prior notice.
The New Drug Application Approval of “AVIGAN® Tablet 200mg” in Japan for the anti-influenza virus drug
|March 24, 2014|
Toyama Chemical Co., Ltd. (Headquarters in Shinjuku-ku, Tokyo; President Masuji Sugata; "Toyama Chemical"), a subsidiary of FUJIFILM Holdings Corporation, announced today that the Japanese Ministry of Health, Labour and Welfare has approved the New Drug Application of " AVIGAN®Tablet 200mg" (Generic name: favipiravir; Development code: T-705; " AVIGAN") for a new tablet-format anti-influenza drug.
Influenza viruses replicate their genes within infected cells to propagate and release new viral particles and to spread the infection to other cells. Neuraminidase inhibitors, typically used in influenza treatment today, inhibit the release of new viral particles to prevent the spread of infection.
AVIGAN has obtained the approval in Japan ahead of other countries after the authorities considered current situations of influenza and recognized significance in making AVIGAN, which has a new mechanism of action, available to establish preparedness against the possible outbreak of novel or re-emerging influenza virus infections, to which neuraminidase inhibitors or other anti-influenza drugs could be ineffective or not sufficiently effective.
AVIGAN is a pharmaceutical product that is to be administered to those infected with novel or re-emerging influenza viruses when the government makes a decision to use it to control such viruses. It is therefore manufactured and distributed upon request by the Minister of Health, Labor and Welfare, rather than immediately being marketed to healthcare providers.
With sincere acknowledgement of social expectations for AVIGAN, Toyama Chemical will establish a stable supply structure to be activated upon request from the Minister of Health, Labor and Welfare, by paying full considerations for distribution management and safety measures.
Toyama Chemical, a subsidiary of FUJIFILM Holdings Corporation, specializes in pharmaceutical research and development, and strives to “contribute to the further development of global health care through new drug development”.